Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2712 - AGATA molecular screening program: implementing precision medicine in patients with advanced breast cancer in Spain.


11 Sep 2017


Poster display session


Translational Research;  Breast Cancer


Sonia Pernas Simon


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


S. Pernas Simon1, P. Villagrasa Gonzalez2, A. Vivancos3, A. Prat4, M. Scaltriti5, O. Burgues6, J. Rodon7, J. Canes Ruiz2, A. Lluch8, A. Llombart9, J. Dorca10, A. Perelló Martorell11, M. Oliveira12, A. Montaño13, L. Garcia-Estevez14, P. Nuciforo15, G. Ribas16, I. Rapado17, L. de la Pena2, E. Ciruelos17

Author affiliations

  • 1 Medical Oncology  , Institut Català d'Oncologia-Hospitalet, 08908 - Barcelona/ES
  • 2 Scientific Department, SOLTI Breast Cancer Research Group, Barcelona/ES
  • 3 Cancer Genomics, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 4 Medical Oncology  , Hospital Clínic de Barcelona  , 8036 - Barcelona/ES
  • 5 Memorial Hospital Research Laboratories, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 6 Pathological Anatomy, Hospital Clínico Universitario de Valencia, 46010 - Valencia/ES
  • 7 Department Of Oncology, Vall d'Hebron University Hospital, Barcelona/ES
  • 8 Medical Oncology  , Hospital Clinico Universitario de Valencia, 46010 - Valencia/ES
  • 9 Medical Oncology  , Hospital Universitario Arnau Vilanova de Lleida, 25198 - Lerida/ES
  • 10 Medical Oncology  , Institut Català d'Oncologia-Girona, Girona/ES
  • 11 Medical Oncology, Hospital Son Espases, Palma de Mallorca/ES
  • 12 Medical Oncology  , Vall d`Hebron University Hospital Institut d'Oncologia, 08035 - Barcelona/ES
  • 13 Medical Oncology, Hospital Virgen del Rocío, Sevilla/ES
  • 14 Medical Oncology, Centro Integral Oncologico Clara Campal, Madrid/ES
  • 15 Molecular Oncology Group, Vall d´Hebron Institute of Oncology, 08035 - Barcelona/ES
  • 16 Medical Oncology, Biomedical Research institute INCLIVA - University of Valencia, 46010 - Valencia/ES
  • 17 Medical Oncology, University Hospital 12 De Octubre, 28041 - Madrid/ES


Abstract 2712


Metastatic breast cancer continues to be a major cause of cancer death among women globally. In recent years, a better understanding of tumor biology, and the availability of high-throughput technologies has enabled the emergence of precision medicine bringing new expectations and giving rise to molecular screening programs worldwide. Recently, the MOSCATO trial has shown for the very first time that prospectively sequencing a large panel of genes and utilizing this information to guide treatment choices may improve the outcome of a subset of patients. Some institutions are implementing such strategy as part of the routine treatment decision-making process. However, SOLTI, as a collaborative Spanish network, runs AGATA, the first multi-institutional molecular screening program ever implemented in this country. Patient recruitment started in October 2014 and is expected to conclude in June 2017.

Trial design

Up to 260 patients with metastatic breast cancer will be recruited in 10 participating sites in Spain. Mutation testing is performed prospectively in the genomic laboratories of Vall d´Hebron Institute of Oncology in Barcelona, 12 de Octubre University Hospital in Madrid, and the University Clinical Hospital of Valencia. Upon molecular characterization and collection of key clinical data, each case is reviewed by a multidisciplinary advisory board, which recommends potential experimental treatments, mainly in the context of clinical trials. During this pilot stage, our primary objective is to determine the success rate in including patients in trials based on their molecular profile. Additional aims are to identify technical and logistical barriers to the implementation of a nationwide program, describe the genomic profiles of the tumors, and assess patient outcomes. Retrospective gene expression (PAM50 + 110 genes and 20 miRNAs) and proteomic analysis (40 markers) will be performed to provide a more comprehensive molecular profile of the tumors that may help explain sensitivity or resistance to administered therapies. Data collected within this program is expected to generate hypotheses for further investigations directed to improve precision medicine.

Clinical trial identification


Legal entity responsible for the study

SOLTI Breast Cancer Research Group


Novartis, Mutua Madrileña, Instituto de Salud Carlos III


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.